Borghi Chiara, Dell'Atti Lucio
Department of Morphology, Surgery and Experimental Medicine, Institute of Obstetrics and Gynecology, University of Ferrara.
Arch Ital Urol Androl. 2017 Mar 31;89(1):7-11. doi: 10.4081/aiua.2017.1.7.
Female Sexual Disorders (FSD) include a complex, multidimensional, individual experience that can change as an individual age, suggesting that these problems are caused by multiple factors including psychosocial factors, personal relationships, pathologic changes caused by diseases, and pharmacologic influences. Menopause is an important time for middle aged women and postmenopausal physiological changes could have a significant role in the development of FSD. Few is still known about their correct definition and treatment. Their incidence, prevalence and risk factors are difficult to define because of a high level of overlap in the experience of problems with desire, arousal, and orgasm. Little evidences are known about the best therapeutic approach, and both non-pharmacological and pharmacological treatment options have been described. Among these, phosphodiesterase type 5 inhibitors could be an effective option for many subtypes of female sexual disorders, with an improvement in different aspects of sexual function, such as desire, arousal, orgasm and sexual satisfaction. In this paper authors reviewed what is already known about the use of these vasoactive agents, particularly tadalafil, as a treatment option for female sexual disturbances.
女性性功能障碍（FSD）包括一种复杂的、多维度的个体体验，这种体验会随着个体年龄的增长而变化，这表明这些问题是由多种因素引起的，包括心理社会因素、人际关系、疾病导致的病理变化以及药物影响。更年期对中年女性来说是一个重要时期，绝经后的生理变化可能在女性性功能障碍的发生发展中起重要作用。关于它们的正确定义和治疗，目前仍知之甚少。由于在性欲、性唤起和性高潮问题的体验上存在高度重叠，它们的发病率、患病率和危险因素难以界定。关于最佳治疗方法的证据很少，非药物和药物治疗方案均有描述。其中，5型磷酸二酯酶抑制剂可能是许多女性性功能障碍亚型的有效选择，可改善性功能的不同方面，如性欲、性唤起、性高潮和性满意度。在本文中，作者回顾了关于使用这些血管活性药物，特别是他达拉非，作为女性性功能障碍治疗选择的已知情况。
